The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis

The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis

(1) <b>Background</b>: Nivolumab plus chemotherapy is established as a first-line treatment for advanced gastric cancer (AGC). While mFOLFOX6 is commonly used for AGC with severe peritoneal metastasis, the efficacy of nivolumab combined with it remains uncertain. We evaluated the outcome...

Full description

Bibliographic Details
Main Authors: Yurika Nakayama, Takayuki Ando, Naoki Takahashi, Kenichiro Tsukada, Hiroaki Takagi, Yuno Goto, Atsuko Nakaya, Naokatsu Nakada, Hiroki Yoshita, Iori Motoo, Akira Ueda, Yuko Ueda, Miho Sakumura, Shinya Kajiura, Kohei Ogawa, Ayumu Hosokawa, Ichiro Yasuda
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Journal of Clinical Medicine
Subjects:
gastric cancer
severe peritoneal metastasis
mFOLFOX6
nivolumab
Online Access:https://www.mdpi.com/2077-0383/13/3/834

Similar Items

Similar Items